RESULTS. Almost 600 patients were randomized to each treatment arm. Almost 75% of patients had a least 1 episode of asthma, with almost half of patients culminating in an exacerbation. No significant difference was seen between groups in the number of episodes leading to asthma exacerbations. Daily montelukast reduced symptoms over the 12-day treatment period of asthma episodes compared with pl...

Long-term follow-up (4 years) of the phase 3 KEYNOTE-048 (NCT02358031) study continued to demonstrate survival benefit with pembrolizumab monotherapy and + chemotherapy vs EXTREME in first-line R/M HNSCC. Pembrolizumab showed significantly longer OS PD-L1 CPS ≥1. Given that or for ≥1 is standard care HNSCC United States, outcomes extended are interest. We present 5 years all patients (pts) from...

1National Addiction Centre, Institute of Psychiatry, King’s College, London, De Crespigny Park, London SE5 8AF, UK, 2Bexley Substance Misuse Service, South London and Maudsley NHS Trust, London, UK and 3Molecular Psychiatry Laboratory, Research Department of Mental Health Sciences, Windeyer Institute of Medical Sciences, University College London Medical School, 46 Cleveland Street, London W1T ...

R. Suresh, K. Srinivasan, D.V. Senthilkumar, I. Raja Mohamed, K. Murali, M. Lakshmanan, and J. Kurths 1 Centre for Nonlinear Dynamics, Department of Physics, Bharathidasan University, Tiruchirapalli 620 024, India 2 Potsdam Institute for Climate Impact Research, 14473 Potsdam, Germany 3 Department of Physics, B. S. Abdur Rahman University, Chennai 600 048, India 4 Department of Physics, Anna Un...

Yukie Yokota 1, Kosei Ueno 2, Hiroaki Misawa 2 and Takuo Tanaka 1,2,3,4,* 1 Metamaterials Laboratory, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan; [email protected] 2 RIES, Hokkaido University, N21W10, Kita-Ward, Sapporo, Hokkaido 001-0021, Japan; [email protected] (K.U.); [email protected] (H.M.) 3 Department of Innovative and Engineered Materials, Tokyo Institute of Technol...